Nektar Therapeutics (NKTR) Enterprise Value (2010 - 2026)

Nektar Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$568.6 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 160.07% year-over-year to -$568.6 million; the TTM figure through Mar 2026 stood at -$568.6 million (down 160.07% YoY), while the FY2025 annual figure was -$245.8 million, up 3.71% from the prior year.
• Enterprise Value was -$568.6 million for Q1 2026 at Nektar Therapeutics, down from -$245.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$175.9 million in Q2 2025 to a low of -$667.0 million in Q1 2022.
• Historically, Enterprise Value has averaged -$377.6 million across 5 years, with a median of -$303.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value surged 40.68% in 2022, then tumbled 160.07% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$505.0 million in 2022, then surged by 39.88% to -$303.6 million in 2023, then grew by 15.94% to -$255.2 million in 2024, then rose by 3.71% to -$245.8 million in 2025, then plunged by 131.37% to -$568.6 million in 2026.
• The last three Enterprise Value figures came in at -$568.6 million (Q1 2026), -$245.8 million (Q4 2025), and -$270.2 million (Q3 2025), per Business Quant data.